These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 17652819)

  • 1. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Hasinoff BB; Herman EH
    Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemistry of dexrazoxane and analogues.
    Hasinoff BB
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of dexrazoxane.
    Hochster HS
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M; Vici P
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
    Synold TW; Tetef ML; Doroshow JH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):93-9. PubMed ID: 9768830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview and historical development of dexrazoxane.
    Hellmann K
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of anthracycline extravasation with dexrazoxane.
    Langer SW; Sehested M; Jensen PB
    Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
    Wu X; Patel D; Hasinoff BB
    J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
    Goey AK; Schellens JH; Beijnen JH; Huitema AD
    Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
    Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
    Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
    Hasinoff BB; Schroeder PE; Patel D
    Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
    Wexler LH
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):86-92. PubMed ID: 9768829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
    Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
    Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
    Langer SW; Jensen PB; Sehested M
    Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexrazoxane use in the prevention of anthracycline extravasation injury.
    Hasinoff BB
    Future Oncol; 2006 Feb; 2(1):15-20. PubMed ID: 16556068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
    Lopez M
    Clin Ter; 1999; 150(1):37-49. PubMed ID: 10367544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.